Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesetaxel plus reduced-dose capecitabine in HER2-, HR+ metastatic breast cancer
NCT03326674Phase 3Terminated
- Sponsor
- Odonate Therapeutics
- Start
- Dec 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of tesetaxel in breast cancer, sponsored by Odonate Therapeutics. Started Dec 2017; status: terminated.
02
Drugs
tesetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03326674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03326674.